Plasma-derived exosomes contributes to endothelial-to-mesenchymal transition in Moyamoya disease
Jilan Liu1, Chao Chen2, Xianyun Qin1
1Department of Medical Research Center, Affiliated Hospital of Jining Medical University, Jining, Shandong, 272029, PR China.
Background:
Moyamoya disease (MMD) is a cerebrovascular disease with a high disability rate; however, its pathogenesis remains unknown. Endothelial-mesenchymal transition (EndMT) is the pathological basis of many vascular diseases; however, the key role of EndMT in MMD has not yet been reported.
Method:
We collected vascular tissues from three control samples and six patients with MMD to detect the expression of EndMT-related genes. To elucidate the mechanism of EndMT in MMD, we performed in vitro cell experiments. Plasma-derived exosomes (PDEs) can transmit information between cells and tissues and are of considerable importance in several disease studies. PDEs were used to stimulate EndMT phenotype in cerebrovascular endothelial cells.
Results:
Multiplex fluorescent immunohistochemistry staining confirmed that CD31, VE-cadherin and E-cadherin down-regulated, whereas α-SMA and vimentin were significantly up-regulated in moyamoya vascular endothelial cells than in control samples. PDEs from MMD patients significantly promoted cell proliferation and migration, resulting in slender cells. PDEs induce EndMT-related phenotype changes in cerebral vascular endothelial cells, including decreased endothelial cell marker expression and increased mesenchymal cell marker expression. We demonstrated that EndMT phenotypic alterations are mediated, in part, by microRNA(miRNAs).
Conclusion:
This study was the first to propose that EndMT may exist in the vessels of patients with MMD. PDEs induce the EndMT phenotype to promote the development of MMD. This study aimed to provide a new theoretical basis for elucidating the pathogenesis of MMD.
Insights
Endothelial-mesenchymal transition (EndMT) plays a key role in Moyamoya disease (MMD) pathogenesis. Plasma-derived exosomes from MMD patients promote EndMT in cerebrovascular cells, offering new insights into MMD development.
Area of Science:
- Vascular Biology
- Cellular Biology
- Pathogenesis Research
Background:
- Moyamoya disease (MMD) is a cerebrovascular disorder with unknown pathogenesis and high disability rates.
- Endothelial-mesenchymal transition (EndMT) is implicated in vascular diseases, but its role in MMD was previously unreported.
Purpose of the Study:
- To investigate the potential role of EndMT in Moyamoya disease.
- To elucidate the mechanism by which plasma-derived exosomes (PDEs) influence EndMT in MMD.
Main Methods:
- Analysis of EndMT-related gene expression in vascular tissues from MMD patients and controls.
- In vitro experiments using cerebrovascular endothelial cells stimulated with PDEs from MMD patients.
- Assessment of phenotypic changes and molecular markers associated with EndMT.
Main Results:
- MMD vascular endothelial cells showed decreased expression of endothelial markers (CD31, VE-cadherin, E-cadherin) and increased expression of mesenchymal markers (α-SMA, vimentin).
- MMD patient-derived PDEs promoted endothelial cell proliferation and migration, inducing an EndMT phenotype.
- MicroRNAs (miRNAs) were identified as mediators of these EndMT phenotypic alterations.
Conclusions:
- This study provides the first evidence of EndMT in Moyamoya disease vasculature.
- MMD patient-derived PDEs induce EndMT, contributing to MMD pathogenesis.
- The findings offer a new theoretical framework for understanding MMD development.
More Related Videos
08:38Author Spotlight: A Neonatal Heterotopic Rat Heart Transplantation Model for the Study of Endothelial-to-Mesenchymal Transition
Published on: July 21, 2023
07:49Molecular Analysis of Endothelial-mesenchymal Transition Induced by Transforming Growth Factor-β Signaling
Published on: August 3, 2018
Related Concept Videos
Overview of Exosomes
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Mesenchymal Stem Cells
